{"id":"W2116956799","doi":"10.1016/s0140-6736(08)60725-4","title":"Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1865,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Internal medicine; Randomization; Randomized controlled trial; Intention-to-treat analysis; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}